It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.
The EU doesn’t do fundamental research, which is why it has taken 20 years for researchers involved in high risk research to get together, but it can’t get by without it.